Compare JPMorgan Chase & Co (JPM) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Mesoblast Limited — how do they compare? JPMorgan Chase & Co trades at $345.21 (market cap $900.78B), while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: JPMorgan Chase & Co is far larger — about 415.1× Mesoblast Limited's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| JPM | MESO | |
|---|---|---|
Market Cap | $900.78B | $2.17B |
Volume | 10,479,943 | — |
Sector | Financials | Technology |
52-Week High | $346.91 | $20.96 |
52-Week Low | $282.84 | $12.88 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $345.23, up 1.21% on the day, with a bullish technical outlook and strong analyst support. The stock shows robust fundamentals with revenue growth from $181.85B in 2025 to a projected $194.8B in 2026, though net income dipped slightly to $57.05B. Recent earnings beats in Q1 and Q2 2026 highlight operational strength, while a moderate buy consensus and $372.73 price target suggest upside potential amid geopolitical and economic uncertainties noted by CEO Jamie Dimon.
JPMorgan presents a favorable investment case driven by earnings momentum and sector leadership, but risks include volatile cash flows, rising cybersecurity threats, and macroeconomic headwinds. Institutional accumulation and a high ROE reinforce confidence, yet investors must weigh debt levels and interest rate sensitivity against the stock's current valuation near key resistance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
